These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36977594)

  • 1. Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1.
    Nchioua R; Schundner A; Klute S; Koepke L; Hirschenberger M; Noettger S; Fois G; Zech F; Graf A; Krebs S; Braubach P; Blum H; Stenger S; Kmiec D; Frick M; Kirchhoff F; Sparrer KM
    Life Sci Alliance; 2023 Jun; 6(6):. PubMed ID: 36977594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells.
    Nchioua R; Schundner A; Kmiec D; Prelli Bozzo C; Zech F; Koepke L; Graf A; Krebs S; Blum H; Frick M; Sparrer KMJ; Kirchhoff F
    J Virol; 2022 Jun; 96(11):e0059422. PubMed ID: 35543509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of SARS-CoV-2 variants of concern in primary human nasal cultures demonstrates Delta as most cytopathic and Omicron as fastest replicating.
    Tanneti NS; Patel AK; Tan LH; Marques AD; Perera RAPM; Sherrill-Mix S; Kelly BJ; Renner DM; Collman RG; Rodino K; Lee C; Bushman FD; Cohen NA; Weiss SR
    mBio; 2024 Apr; 15(4):e0312923. PubMed ID: 38477472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant.
    Laine L; Skön M; Väisänen E; Julkunen I; Österlund P
    Front Immunol; 2022; 13():1016108. PubMed ID: 36248817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of SARS-CoV-2 by type I and type III interferons.
    Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
    J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
    Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
    Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
    Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
    J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omicron-induced interferon signaling prevents influenza A H1N1 and H5N1 virus infection.
    Bojkova D; Bechtel M; Rothenburger T; Kandler JD; Hayes L; Olmer R; Martin U; Jonigk D; Ciesek S; Wass MN; Michaelis M; Cinatl J
    J Med Virol; 2023 Mar; 95(3):e28686. PubMed ID: 36938992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Airway epithelial interferon response to SARS-CoV-2 is inferior to rhinovirus and heterologous rhinovirus infection suppresses SARS-CoV-2 replication.
    Vanderwall ER; Barrow KA; Rich LM; Read DF; Trapnell C; Okoloko O; Ziegler SF; Hallstrand TS; White MP; Debley JS
    Sci Rep; 2022 Apr; 12(1):6972. PubMed ID: 35484173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells.
    Gori Savellini G; Anichini G; Cusi MG
    Virus Res; 2023 Jul; 332():199134. PubMed ID: 37192725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
    Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
    Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
    Zhu Y; Hu Y; Liu N; Chong H; He Y
    Antiviral Res; 2022 Dec; 208():105445. PubMed ID: 36265805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
    Pérez-Vargas J; Shapira T; Olmstead AD; Villanueva I; Thompson CAH; Ennis S; Gao G; De Guzman J; Williams DE; Wang M; Chin A; Bautista-Sánchez D; Agafitei O; Levett P; Xie X; Nuzzo G; Freire VF; Quintana-Bulla JI; Bernardi DI; Gubiani JR; Suthiphasilp V; Raksat A; Meesakul P; Polbuppha I; Cheenpracha S; Jaidee W; Kanokmedhakul K; Yenjai C; Chaiyosang B; Teles HL; Manzo E; Fontana A; Leduc R; Boudreault PL; Berlinck RGS; Laphookhieo S; Kanokmedhakul S; Tietjen I; Cherkasov A; Krajden M; Nabi IR; Niikura M; Shi PY; Andersen RJ; Jean F
    Antiviral Res; 2023 Jan; 209():105484. PubMed ID: 36503013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 mRNA vaccine protects against SARS-CoV-2 Omicron BA.1 infection in diet-induced obese mice through boosting host innate antiviral responses.
    Chen Y; Song W; Li C; Wang J; Liu F; Ye Z; Ren P; Tong Y; Li J; Ou Z; Lee AC; Cai JP; Wong BH; Chan JF; Yuen KY; Zhang AJ; Chu H
    EBioMedicine; 2023 Mar; 89():104485. PubMed ID: 36857860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon resistance of emerging SARS-CoV-2 variants.
    Guo K; Barrett BS; Morrison JH; Mickens KL; Vladar EK; Hasenkrug KJ; Poeschla EM; Santiago ML
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2203760119. PubMed ID: 35867811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type-II IFN inhibits SARS-CoV-2 replication in human lung epithelial cells and ex vivo human lung tissues through indoleamine 2,3-dioxygenase-mediated pathways.
    Yang D; Chan JF; Yoon C; Luk TY; Shuai H; Hou Y; Huang X; Hu B; Chai Y; Yuen TT; Liu Y; Zhu T; Liu H; Shi J; Wang Y; He Y; Sit KY; Au WK; Zhang AJ; Yuan S; Zhang BZ; Huang YW; Chu H
    J Med Virol; 2024 Feb; 96(2):e29472. PubMed ID: 38373201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.